111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform in China,  announced today that it has started to offer free online consultation service to Chinese nationals living and working abroad through its Internet hospital since March 17. This expands the Company's pioneering efforts to combat the outbreak, by providing including free online consultations to the large numbers of Chinese living, working, or visiting overseas. 

Equipped with a professional medical team of more than 2,000 doctors, 111's platform is capable of providing real-time online consultation services to Chinese nationals living and working abroad, as well as potentially to the more than 60 million overseas Chinese, mostly residing in Southeast Asia. The newly launched Chinese-language service covers 11 categories including general outpatient, pediatrics, internal medicine and gynecology and obstetrics. In the meantime, 111 has also placed a portal to the service at a prominent position on its app homepage with a clear reminder, so that users of the app can easily locate and access the service. 

As a major cloud-based healthcare service provider and leading Internet healthcare platform in China's fight against the virus, 111 has provided free online consultation service through its Internet hospital since a national emergency was declared against the outbreak of COVID-19 on January 23. The service has served as an important complement to offline medical resources and effectively helps to minimize the risk of hospital-acquired contagion.

During the outbreak, the number of new registered users on 111's App has increased over fivefold and the number of new patients with chronic diseases has increased more than threefold. With the assistance of artificial intelligence ("AI") technology, individual doctors on 111's platform have provided as many as 300 consultations per day.

Mr. Pengcheng Zhu, Co-COO of 111, commented, "Online medical service is emerging as the 'second battlefield' in China's efforts on prevention and control of the virus. By leveraging our cloud capabilities, 111 will continue to help Chinese people around the world combat the outbreak with our cloud-based free online consultation service."

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

About 111, Inc.

111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading integrated online and offline healthcare platform in China. The Company provides hundreds of millions of consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy and indirectly through its offline pharmacy network. 111 also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation and electronic prescription services. In addition to providing direct services to consumers through its online retail pharmacy, 111 also enables offline pharmacies to better serve their customers. The Company's online wholesale pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. The Company's new retail platform, by integrating the front and back ends of the pharmaceutical supply chain, has formed a smart supply chain, which transforms the flow of pharmaceutical products to pharmacies and modernizes how they serve their customers.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.